1. Home
  2. ALLO vs LPTH Comparison

ALLO vs LPTH Comparison

Compare ALLO & LPTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • LPTH
  • Stock Information
  • Founded
  • ALLO 2017
  • LPTH 1985
  • Country
  • ALLO United States
  • LPTH United States
  • Employees
  • ALLO N/A
  • LPTH N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • LPTH Semiconductors
  • Sector
  • ALLO Health Care
  • LPTH Technology
  • Exchange
  • ALLO Nasdaq
  • LPTH Nasdaq
  • Market Cap
  • ALLO 252.9M
  • LPTH 229.5M
  • IPO Year
  • ALLO 2018
  • LPTH 1996
  • Fundamental
  • Price
  • ALLO $1.44
  • LPTH $8.47
  • Analyst Decision
  • ALLO Buy
  • LPTH Strong Buy
  • Analyst Count
  • ALLO 12
  • LPTH 3
  • Target Price
  • ALLO $8.80
  • LPTH $6.83
  • AVG Volume (30 Days)
  • ALLO 2.9M
  • LPTH 1.9M
  • Earning Date
  • ALLO 11-06-2025
  • LPTH 11-06-2025
  • Dividend Yield
  • ALLO N/A
  • LPTH N/A
  • EPS Growth
  • ALLO N/A
  • LPTH N/A
  • EPS
  • ALLO N/A
  • LPTH N/A
  • Revenue
  • ALLO N/A
  • LPTH $37,202,630.00
  • Revenue This Year
  • ALLO N/A
  • LPTH $50.36
  • Revenue Next Year
  • ALLO $100.00
  • LPTH $7.77
  • P/E Ratio
  • ALLO N/A
  • LPTH N/A
  • Revenue Growth
  • ALLO N/A
  • LPTH 17.26
  • 52 Week Low
  • ALLO $0.86
  • LPTH $1.40
  • 52 Week High
  • ALLO $3.78
  • LPTH $9.34
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 64.79
  • LPTH 68.63
  • Support Level
  • ALLO $1.29
  • LPTH $6.47
  • Resistance Level
  • ALLO $1.43
  • LPTH $9.34
  • Average True Range (ATR)
  • ALLO 0.07
  • LPTH 0.69
  • MACD
  • ALLO 0.02
  • LPTH 0.06
  • Stochastic Oscillator
  • ALLO 78.17
  • LPTH 82.90

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About LPTH LightPath Technologies Inc.

LightPath Technologies Inc is a manufacturer, distributor, and integrator of proprietary optical components and assemblies. It is also engaged in the research and development for optical solutions for the traditional optics markets and communications markets. The company's business based on the following product groups: precision molded optics, specialty products, and infrared products. It currently serves the following major markets, distribution and catalog, laser, industrial, instrumentation, telecommunications, and defense.

Share on Social Networks: